The standard starting dose for ponatinib is 45 mg. That being said, many clinicians lower the dose to 30 mg or 15 mg once a response is achieved in an effort to lower the rates of adverse events. The ongoing OPTIC study is evaluating if it is safe/effective to start at lower doses. An interim analys...